13 Marzo 2026

ILC

Weight loss is associated with improvements in histological features of non-alcoholic steatohepatitis #ILC2015 #LiverHome

Weight loss is associated with improvements in histological features of non-alcoholic steatohepatitis #ILC2015 #LiverHome

Redazione 26 Aprile 2015
New data presented at The International Liver CongressTM 2015 show that the intensity of weight loss induced...
Per saperne di più Maggiori informazioni su Weight loss is associated with improvements in histological features of non-alcoholic steatohepatitis #ILC2015 #LiverHome
Herbal remedy derived from milk thistle demonstrates efficacy in non-alcoholic steatohepatitis #ILC2015 #LiverHome

Herbal remedy derived from milk thistle demonstrates efficacy in non-alcoholic steatohepatitis #ILC2015 #LiverHome

Redazione 25 Aprile 2015
Results from a double-blind, placebo-controlled study of silymarin, which is derived from the milk thistle plant, have...
Per saperne di più Maggiori informazioni su Herbal remedy derived from milk thistle demonstrates efficacy in non-alcoholic steatohepatitis #ILC2015 #LiverHome
Investigational anti-diabetic compound may offer potential for management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis #ILC2015 #LiverHome

Investigational anti-diabetic compound may offer potential for management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis #ILC2015 #LiverHome

Redazione 25 Aprile 2015
Data presented at The International Liver Congressâ„¢ 2015 demonstrates that remogliflozin etabonate, an investigational drug in type...
Per saperne di più Maggiori informazioni su Investigational anti-diabetic compound may offer potential for management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis #ILC2015 #LiverHome
EASL Congress: faldaprevir ha dimostrato un alto tasso di guarigione dal virus HCV

EASL Congress: faldaprevir ha dimostrato un alto tasso di guarigione dal virus HCV

Redazione 30 Aprile 2013
I risultati dello studio di Fase III STARTVersoâ„¢1  con faldaprevir+ (BI 201335), inibitore di proteasi sperimentale in monosomministrazione giornaliera,...
Per saperne di più Maggiori informazioni su EASL Congress: faldaprevir ha dimostrato un alto tasso di guarigione dal virus HCV
EASL, Chronic Hepatitis C: Phase II Trial Evaluating Investigational NS3/ 4A Protease Inhibitor MK-5172 #ILC2013

EASL, Chronic Hepatitis C: Phase II Trial Evaluating Investigational NS3/ 4A Protease Inhibitor MK-5172 #ILC2013

Redazione 28 Aprile 2013
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of...
Per saperne di più Maggiori informazioni su EASL, Chronic Hepatitis C: Phase II Trial Evaluating Investigational NS3/ 4A Protease Inhibitor MK-5172 #ILC2013